ProtoKinetix announced the completion of an in vivo study to assess the effect of AAGP on the long term survival and functional activity of photoreceptor precursor cells (PPCs) in the animal ocular model of genetic retinal degeneration.
The objective of this study was to determine the effect of 24-hour pre-treatment with anti-aging glycoprotein (AAGP) PKX-001 at 4 mg/mL on the long-term (3, 4.5 and 6 months) survival and functional activity of PPCs) following their subretinal transplantation into the eye of nude immunocompromised rats with genetic retinal degeneration.
In vivo tests demonstrated that transplantation of PPCs pre-treated with AAGP (PKX-001) results in statistically significant improvements in both the visual behavioral (optokinetic tracking test) and functional analysis (electroretinogram test) responses as compared with PPCs without pre-treatment. Imaging data revealed that pre-treatment of PPCs with AAGP also leads to a substantial enhancement of cell survival as determined at 3, 4.5 and 6 months after cell transplantation. At the 6-month time point, the AAGP-treated cells acquired the ability to express retinal and synaptic proteins, confirming that AAGP has no adverse effect on precursor cells’ maturation.
The study was conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
“AAGP is proving itself to be a very useful pharmaceutical for markedly improving cell survival when transplanted into model systems,” Kevin Gregory-Evans, MD, PhD, FRCS, FRCOphth, said in the news release. “That this is important is proven by the functional benefits we are seeing in these models that would now warrant clinical trials.”
The success of these tests opens doors for ProtoKinetix AAGP® in the entire field of regenerative medicine. The next step towards commercialization is partnering with a major pharma to adapt AAGP® into their current clinical trial program. The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.